Health
26 articles
HealthIntermittent fasting heart risk: study shocks
A new study reveals that intermittent fasting may significantly raise cardiovascular death risk, alarming millions of dieters.
HealthFDA combo test flu COVID RSV: new home toolkit
FDA authorized the first at-home combo test for flu, COVID, and RSV. This multiplex molecular test could redefine home diagnostics this winter.
HealthMedtronic insulin pump recall: why it's a nightmare
The Medtronic insulin pump recall exposes critical cybersecurity flaws that put diabetic patients at risk. A must-read analysis.
HealthFDA red dye No.3 ban: 35-year science fight
FDA red dye No.3 ban forces food and pharma to scramble. The hidden science: why a 1960 law finally caught up with a ubiquitous additive.
HealthMicroplastics in brain: a silent pandemic?
Microplastics in brain tissue are rising. A new Nature Medicine study reveals alarming concentrations and links to potential neurological damage.
HealthPancreatic cancer vaccine trial failure: a setback for immunotherapy
A late-stage trial for a pancreatic cancer vaccine failed to improve survival, dashing hopes for a new immunotherapy approach.
HealthRSV vaccine FDA panel rejection analysis
RSV vaccine FDA panel rejection changes everything. This decision impacts millions of seniors and the future of mRNA vaccines for respiratory viruses.
HealthH5N1 bird flu: how severe case sparks new alarm
CDC reports first severe H5N1 bird flu hospitalization in U.S. — a sign the virus may be adapting.
HealthFDA panel rejects COVID-19 vaccine update
In a surprise vote, FDA advisors rejected updating COVID-19 vaccines for fall 2025, citing insufficient data on new variants. The FDA panel rejects COVID-19 vaccine update, altering booster plans.
HealthFDA Alzheimer's Drug Approval: A Logistical Nightmare
The FDA Alzheimer's drug approval for Eli Lilly's Kisunla creates a logistical nightmare with complex dosing and monitoring requirements that challenge healthcare infrastructure.
HealthProstate cancer gene therapy: FDA's first approval is a double-edged sword
FDA's historic approval of a CAR-T-based prostate cancer gene therapy marks a turning point in oncology, but cost and complexity loom.
